268 related articles for article (PubMed ID: 22500881)
21. Pharmacokinetics and bioavailability of tildipirosin following intravenous and subcutaneous administration in sheep.
Abu-Basha EA; Bani Ismail Z; Abu Alhaijaa H; Hamzeh E; Idkaidek NM
J Vet Pharmacol Ther; 2021 Jan; 44(1):79-85. PubMed ID: 32748450
[TBL] [Abstract][Full Text] [Related]
22. Tilmicosin- and florfenicol-loaded hydrogenated castor oil-solid lipid nanoparticles to pigs: Combined antibacterial activities and pharmacokinetics.
Ling Z; Yonghong L; Junfeng L; Li Z; Xianqiang L
J Vet Pharmacol Ther; 2018 Apr; 41(2):307-313. PubMed ID: 29139136
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and bioavailability of tildipirosin in rabbits following single-dose intravenous and intramuscular administration.
Xiong J; Xu Y; He S; Zhang Y; Wang Z; Wang S; Jiang H
J Vet Pharmacol Ther; 2020 Sep; 43(5):448-453. PubMed ID: 32542744
[TBL] [Abstract][Full Text] [Related]
24. Visualizing the 16-membered ring macrolides tildipirosin and tilmicosin bound to their ribosomal site.
Poehlsgaard J; Andersen NM; Warrass R; Douthwaite S
ACS Chem Biol; 2012 Aug; 7(8):1351-5. PubMed ID: 22563863
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
J Vet Pharmacol Ther; 2017 Oct; 40(5):505-516. PubMed ID: 28090673
[TBL] [Abstract][Full Text] [Related]
26. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
Dorey L; Pelligand L; Lees P
BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and Pharmacodynamics of Tildipirosin Against
Zeng D; Sun M; Lin Z; Li M; Gehring R; Zeng Z
Front Microbiol; 2018; 9():1038. PubMed ID: 29867911
[TBL] [Abstract][Full Text] [Related]
28. Activity of florfenicol for Actinobacillus pleuropneumoniae and Pasteurella multocida using standardised versus non-standardised methodology.
Dorey L; Hobson S; Lees P
Vet J; 2016 Dec; 218():65-70. PubMed ID: 27938711
[TBL] [Abstract][Full Text] [Related]
29. Postantibiotic and physiological effects of tilmicosin, tylosin, and apramycin at subminimal and suprainhibitory concentrations on some swine and bovine respiratory tract pathogens.
Diarra MS; Malouin F; Jacques M
Int J Antimicrob Agents; 1999 Aug; 12(3):229-37. PubMed ID: 10461841
[TBL] [Abstract][Full Text] [Related]
30. In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs.
Blackall PJ; Asakawa T; Graydon RJ; White M; Adamson M; Wade LK; Lowe LB
Aust Vet J; 1995 Jan; 72(1):35-6. PubMed ID: 8787526
[No Abstract] [Full Text] [Related]
31. Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology.
Godinho KS; Keane SG; Nanjiani IA; Benchaoui HA; Sunderland SJ; Jones MA; Weatherley AJ; Gootz TD; Rowan TG
Vet Ther; 2005; 6(2):113-21. PubMed ID: 16094559
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic/pharmacodynamic assessment of cefquinome against Actinobacillus Pleuropneumoniae in a piglet tissue cage infection model.
Zhang L; Wu X; Huang Z; Zhang N; Wu Y; Cai Q; Shen X; Ding H
Vet Microbiol; 2018 Jun; 219():100-106. PubMed ID: 29778180
[TBL] [Abstract][Full Text] [Related]
33. Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine.
Sun D; Mi K; Hao H; Xie S; Chen D; Huang L
BMC Vet Res; 2020 Sep; 16(1):366. PubMed ID: 32993661
[TBL] [Abstract][Full Text] [Related]
34. Brazilian Clinical Strains of
Kuchiishi SS; Ramos Prigol S; Bresolin E; Fernandes Lenhard B; Pissetti C; García-Iglesias MJ; Gutiérrez-Martín CB; Martínez-Martínez S; Kreutz LC; Frandoloso R
Antibiotics (Basel); 2023 Nov; 12(12):. PubMed ID: 38136692
[TBL] [Abstract][Full Text] [Related]
35. In vitro susceptibility of Actinobacillus pleuropneumoniae strains to 42 antimicrobial agents.
Gutiérrez CB; Píriz S; Vadillo S; Rodríguez Ferri EF
Am J Vet Res; 1993 Apr; 54(4):546-50. PubMed ID: 8484573
[TBL] [Abstract][Full Text] [Related]
36. In vitro microbiological characterization of novel macrolide CP-163,505 for animal health specific use.
Norcia LJ; Seibel SB; Kamicker BJ; Lemay MA; Lilley SC; Hecker SJ; Bergeron JM; Retsema JA; Hayashi SF
J Antibiot (Tokyo); 1998 Feb; 51(2):136-44. PubMed ID: 9544934
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
[TBL] [Abstract][Full Text] [Related]
38. Changes in antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from pigs in Spain during the last decade.
Gutiérrez-Martín CB; del Blanco NG; Blanco M; Navas J; Rodríguez-Ferri EF
Vet Microbiol; 2006 Jun; 115(1-3):218-22. PubMed ID: 16431040
[TBL] [Abstract][Full Text] [Related]
39. Experimental model of swine pneumonic pasteurellosis using crude Actinobacillus pleuropneumoniae cytotoxin and Pasteurella multocida given endobronchially.
Chung WB; Bäckström LR; Collins MT
Can J Vet Res; 1994 Jan; 58(1):25-30. PubMed ID: 8143249
[TBL] [Abstract][Full Text] [Related]
40. Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine.
Moore GM; Mowrey DH; Tonkinson LV; Lechtenberg KF; Schneider JH
Am J Vet Res; 1996 Feb; 57(2):220-3. PubMed ID: 8633812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
